Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06FPF
|
||||
| Former ID |
DIB015064
|
||||
| Drug Name |
Valortim
|
||||
| Synonyms |
Anthrax antibody, Medarex; MDX-1303; Anthrax antibody, Medarex/PharmAthene; Anti-B anthracis, Bristol Myers Squibb/PharmAthene; Anti-B anthracis PA (anthrax), Medarex/BMS/PharmAthene
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10:A00-B99] | Phase 1 | [1] | ||
| Company |
Pharmathene
|
||||
| Target and Pathway | |||||
| Target(s) | Protective antigen | Target Info | [2] | ||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | ||||
| Reactome | Uptake and function of anthrax toxins | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01265745) Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects. U.S. National Institutes of Health. | ||||
| REF 2 | Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.